Hua Lin

US Patent:

20020155601, Oct 24, 2002

Filed:

Jan 2, 2002

Appl. No.:

10/032495

Inventors:

Wen Yan - Potomac MD, US
Steve Huang - Germantown MD, US
Minh-Thanh Nguyen - Rockville MD, US
Hua Lin - Potomac MD, US
Jingqi Lei - Gaithersburg MD, US
Ruchi Khanna - Gemantown MD, US

International Classification:

A61K048/00
C12Q001/68
C12N005/08

US Classification:

435/366000, 435/006000, 424/093210

Abstract:

A method of producing a homogenous population of homozygous stem (HS) cells pre-selected for immunotype and/or genotype from donor cells is described herein. The invention relates to methods of using immunohistocompatible HS cells for diagnosis, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, traumatic injuries and cancer. The invention further relates to methods for using histocompatible HS stem cells pre-selected for a non-disease genotype for prophylactic and therapeutic intervention including, but not limited to, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, and cancer. Furthermore, the invention relates to a catalogued transplant depository of HS cells derived from multiple donors, each of the HS cells being homozygous for a unique HLA haplotype, for the purpose of having a constant, reliable, comprehensive supply of immunohistocompatible cells for diagnosis, treatment and/or transplantation.

US Patent:

20020168763, Nov 14, 2002

Filed:

Nov 30, 2001

Appl. No.:

09/997240

Inventors:

Wen Yan - Potomac MD, US
Steve Huang - Germantown MD, US
Minh-Thanh Nguyen - Rockville MD, US
Hua Lin - Potomac MD, US
Jingqi Lei - Gaithersburg MD, US
Ruchi Khanna - Germantown MD, US

International Classification:

C12N005/06
C12N005/08

US Classification:

435/325000, 435/354000, 435/366000, 435/350000

Abstract:

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.

US Patent:

20040053272, Mar 18, 2004

Filed:

Mar 3, 2003

Appl. No.:

10/377033

Inventors:

Steven Huang - Germantown MD, US
Hua Lin - North Potomac MD, US

International Classification:

C12Q001/68
G01N033/53
G01N033/567
C12N005/08

US Classification:

435/006000, 435/007200, 435/455000, 435/366000

Abstract:

The present invention relates to materials and methods for the quantitative and qualitative analysis of gene expression during targeted differentiation of isolated homozygous stem cells, and to materials and methods for accumulating sequence tags sampled from a population of expressed genes. More particularly, the present invention relates to a method for constructing a model of cellular development and differentiation comprising the steps of: (1) producing a homogenous population of homozygous stem (HS) cells; (2) directing the differentiation of the HS cells to arrive at desired mature (somatic) cells, group of cells or tissue; (3) periodically sampling HS cells undergoing differentiation to extract total cellular RNA produced at various sampling stages; (4) isolating mRNA from the total cellular RNA; and (5) constructing a cDNA library representative of proteins produced and expressed at various stages of differentiation, over the course of time. The present invention further relates to sequencing and cataloguing isolated mRNAs and cDNAs at various stages of differentiation of HS cells, producing and cataloguing isolated polypeptides sequences encoded by same, and screening the cDNA libraries. In vitro and in vivo cultures of homozygous stem cell are also described; such cultures find utility both as models of differentiation as well as sources of differentiated tissues and organs.

US Patent:

20080260707, Oct 23, 2008

Filed:

Apr 4, 2008

Appl. No.:

12/078799

Inventors:

Wen Liang Yan - Potomac MD, US
Steve Chien-Wen Huang - Germantown MD, US
Minh-Thanh Nguyen - Rockville MD, US
Hua Helen Lin - North Potomac MD, US
Jingqi Lei - Gaithersburg MD, US
Ruchi Khanna - Germantown MD, US

Assignee:

Stemron, Inc. - Rockville MD

International Classification:

A61K 35/12
A61K 48/00
C12N 5/08
C12N 15/63
A61P 43/00

US Classification:

424 9321, 435455, 435366

Abstract:

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.

US Patent:

20220185797, Jun 16, 2022

Filed:

Mar 25, 2020

Appl. No.:

17/598695

Inventors:

- New York NY, US
- Weston MA, US
Donald W. LANDRY - New York NY, US
Robert J. DEVITA - Westfield NJ, US
Hua V. LIN - Zionsville IN, US
Yunkyoung LEE - New York NY, US
Domenico ACCILI - New York NY, US
Sandro BELVEDERE - Weston MA, US

International Classification:

C07D 403/04
A61K 31/713
A61K 31/4184
A61K 31/496
C07D 401/14
A61K 31/454
C07D 405/14
C07D 413/14
A61K 31/423
A61K 31/4709
A61K 31/4439
C07D 471/04
A61K 31/437

Abstract:

Various embodiments relate to a compound (represented by Formula I) or a pharmaceutically acceptable salt or tautomer thereof. The compound may selectively inhibit a Forkhead Box O1 (FOXO1) transcription factor. Various embodiments relate to methods comprising administering to a mammal having a disease or disorder associated with impaired pancreatic endocrine function, a therapeutically effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof. Various embodiments relate to methods for producing enteroendocrine cells that make and secrete insulin in a mammal, comprising administering to the mammal an effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof.

US Patent:

20070031859, Feb 8, 2007

Filed:

Mar 31, 2006

Appl. No.:

11/393820

Inventors:

Wen Yan - Potomac MD, US
Steve Huang - Germantown MD, US
Minh-Thanh Nguyen - Rockville MD, US
Hua (Helen) Lin - N. Potomac MD, US
Jingqi Lei - Gaithersburg MD, US
Ruchi Khanna - Germantown MD, US

International Classification:

C12Q 1/68
C12N 5/08
C12N 5/06

US Classification:

435006000, 435455000, 435325000, 435366000

Abstract:

A method of producing a homogenous population of homozygous stem (HS) cells pre-selected for immunotype and/or genotype from donor cells is described herein. The invention relates to methods of using immunohistocompatible HS cells for diagnosis, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, traumatic injuries and cancer. The invention further relates to methods for using histocompatible HS stem cells pre-selected for a non-disease genotype for prophylactic and therapeutic intervention including, but not limited to, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, and cancer. Furthermore, the invention relates to a catalogued transplant depository of HS cells derived from multiple donors, each of the HS cells being homozygous for a unique HLA haplotype, for the purpose of having a constant, reliable, comprehensive supply of immunohistocompatible cells for diagnosis, treatment and/or transplantation.